Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9708283 | 0.98 | ADORA3 (0.41) | ADORA3ADORA2AADORA1ADORA2BAGTR1 | |
| SCHEMBL9708004 | 0.97 | ADORA3 (0.40) | ADORA3ADORA2AADORA1ADORA2BAGTR1 | |
| SCHEMBL9707297 | 0.95 | ADORA3 (0.43) | ADORA3ADORA2AADORA1ADORA2BAGTR1 | |
| SCHEMBL9707529 | 0.95 | ADORA3 (0.43) | ADORA3ADORA2AADORA1ADORA2BAGTR1 | |
| SCHEMBL9708878 | 0.95 | ALOX15 (0.41) | ADORA3ADORA1AGTR1AGTR2 | |
| SCHEMBL9708734 | 0.95 | ALOX15 (0.41) | ADORA3AGTR1AGTR2 | |
| SCHEMBL9708153 | 0.95 | ADORA3 (0.40) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL9708058 | 0.95 | ADORA3 (0.40) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL9708448 | 0.95 | ADORA3 (0.40) | ADORA3ADORA2AADORA1ADORA2BAGTR1 | |
| SCHEMBL9708090 | 0.94 | ADORA3 (0.39) | ADORA3ADORA2AADORA1AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992007852-A1 | BIPHENYLALKYL XANTHINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |